Commenced in January 2007
Frequency: Monthly
Edition: International
Paper Count: 30669
Prevalence of Epstein-Barr Virus Latent Membrane Protein-1 in Jordanian Patients with Hodgkin's Lymphoma and Non- Hodgkin's Lymphoma

Authors: Fawzi Irshaid, Adnan Jaran, Fatiha Dilmi, Khaled Tarawneh, Raji Hadeth, Ahad Al-Khatib

Abstract:

The aim of this study was to estimate the frequency of EBV infection in Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL) occurring in Jordanian patients. A total of 55 patients with lymphoma were examined in this study. Of 55 patients, 30 and 25 were diagnosed as HL and NHL, respectively. The four HL subtypes were observed with the majority of the cases exhibited the mixed cellularity (MC) subtype followed by the nodular sclerosis (NS). The high grade was found to be the commonest subtype of NHL in our sample, followed by the low grade. The presence of EBV virus was detected by immunostating for expression of latent membrane protein-1 (LMP-1). The frequency of LMP-1 expression occurred more frequent in patients with HL (60.0%) than in patients with NHL (32.0%). The frequency of LMP-1 expression was also higher in patients with MC subtype (61.11%) than those patients with NS (28.57%). No age or gender difference in occurrence of EBV infection was observed among patient with HL. By contrast, the prevalence of EBV infection in NHL patients aged below 50 was lower (16.66%) than in NHL patients aged 50 or above (46.15%). In addition, EBV infection was more frequent in females with NHL (38.46%) than in male with NHL (25%). In NHL cases, the frequency of EBV infection in intermediate grade (60.0%) was high when compared with frequency of low (25%) or high grades (25%). In conclusion, analysis of LMP-1 expression indicates an important role for this viral oncogene in the pathogenesis of EBV-associated malignant lymphomas. These data also support the previous findings that people with EBV may develop lymphoma and that efforts to maintain low lymphoma should be considered for people with EBV infection.

Keywords: Infection, Hodgkin lymphoma, Epstein Barr virus, hematoxylin, LMP-1 expression

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1072315

Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 1139

References:


[1] N. L. Harris, E. S. Jaffe and J. O. Armitage, et al., "Lymphoma classification: from R.E.A.L. to W.H.O. and beyond," Cancer: Principles and Practice of Oncology Updates, vol. 13, pp. 1-14, 1999.
[2] J. Stjernswa¨rd, F. Ferris, S. Khleif, W. Jamous, I. Treish, M. Milhem, M. Bushnaq, A. Al Khateib, N. Al-Shtiat, M. Wheeler, and A. Alwan, "Jordan palliative care initiative: A WHO demonstration project," Journal of Pain and Symptom Management, vol. 33, pp. 628-633, 2007.
[3] A. Jemal, A. Thomas, T. Murray, and M. Thun, "Cancer statistics CA," Cancer J. Clin. Vol. 52, pp. 23-47, 2002.
[4] J. G. Gribben, "How I treat indolent lymphoma," Blood, vol. 109, pp. 4617-4626, 2002.
[5] L. B. Travis, "Evaluation of the risk of therapy-associated complications in survivors of Hodgkin Lymphoma," Hematology, vol. 1, pp. 192-196, 2007.
[6] J. S. Knight, A. Tsodikov, D. M. Cibrik, C. W. Ross, M. S. Kaminski, and D. W. Blayney, "Lymphoma after solid organ transplantation: Risk, response to therapy, and survival at a transplantation center," J. Clin. Oncol., vol. 27, pp. 3354-3362, 2009.
[7] K. Hemminki, P. Lenner, J. Sundquist, and J. L. Bermejo, "Risk of subsequent solid tumors after non-Hodgkin's lymphoma: Effect of diagnostic age and time since diagnosis," J. Clin. Oncol., vol. 26, pp. 1850-1857, 2008.
[8] S. B. Pattle, and P. J. Farrell, "The role of Epstein-Barr virus in cancer," Expert Opin. Biol. Ther., Vol. 6, pp. 1193-1205, 2006.
[9] D. Serraino, P. Piselli, C. Angeletti, M. Scuderi, and M. R. Ippolito, "Infection with Epstein-Barr virus and cancer: an epidemiological review," J. Biol. Regul. Homeost. Agents, vol. 19, pp. 63-70, 2005.
[10] J. I. Cohen, "Epstein-Barr virus infection," N. Engl. J. Med., vol. 343, pp. 481-492, 2000.
[11] G. Kapatai, and P. Murray, "Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma," J. Clin. Pathol., vol. 60, pp. 1342-1349, 2007.
[12] D. A. Thorley-Lawson, and A. Gross, "Persistence of the Epstein-Barr virus and the origins of associated lymphomas," N. E. J. M., vol. 350, pp. 1328-1337, 2004.
[13] L. H. Kim, S. C. Peh, and S. Poppema, "Expression of retinoblastoma protein and p16 proteins in classic Hodgkin's lymphoma: relationship with expression of p53 and presence of Epstein-Barr virus in the regulation of cell growth and death," Journal of Human Pathology, vol. 37, pp. 92-100, 2006.
[14] P. Zhao, Y. Lu, L. Liu, and M. Zhong, "Aberrant expression of ID2 protein and its correlation with EBV-LMP1 and p16 (INK4A) in Classical Hodgkin's Lymphoma in China," BioMed Central journal, vol. 8, pp. 1471-2407, 2008.
[15] L. M. Staudt, "The molecular and cellular origins of Hodgkin-s disease," The Journal of Experimental Medicine, vol. 191, pp. 207-212, 2002.
[16] W. J. Haddadin, "Malignant lymphoma in Jordan: a retrospective analysis of 347 cases according to the World Health Organization classification," Annals of Saudi Medicine, vol. 25, pp. 398-403, 2005.
[17] S. Bamanikar, S. Thunold, K. R. Devi, and A. Bamanikar, "The pattern of malignant lymphoma in Oman," Tropical Medicine and Hygiene Journal, vol. 98, pp. 351-354, 1995.
[18] D. K. Shome, S. M. George, F. Al-Hilli, and A. A. Satir, "Spectrum of malignant lymphomas in Bahrain. Leitmotif of a regional pattern," Saudi Medicine Journal, vol. 25, pp. 146-167, 2004.
[19] A. Castella, S. Joshi, T. Raaschou, and N. Mason, "Pattern of Malignant Lymphoma in the United Arab Emirates," Acta Oncologica, vol. 40, pp. 660-664, 2001.
[20] A. S. Soliman, and P. Boffetta, "lymphoma and leukemia," Middle East Cancer Consortium (MECC) Registries, 2004.
[21] N. M. Almasri, "Hodgkin-s lymphoma in north Jordan. Does it have different pattern," Saudi Medical Journal, vol. 25, pp. 1971-1921, 2004.
[22] W. K. Ridha, "Epstein Barr Virus-Mediated deregulation of cell cycle pathways in malignant lymphomas: implication of NFKB, p53, p27 and the mutant p21 Ras using in situ technique," Ph. D. Thesis, University of AL-Nahrain, Iraq, 2004.
[23] S. A. Pileri, S. Ascani, L. Leoncini, E. Sabattini, P. L. Zinzani, P. P. Piccaluga, A. Pileri, M. Giunti, B. Falini, G. B. Bolis, and H. Stein, "Hodgkin-s lymphoma: the pathologist-s viewpoint," Journal of Clinical, vol. 55, pp. 162-176, 2002.
[24] J. O. Thomas, and M. A. Abdullah, "Malignant lymphoma in western province of Saudi Arabia," East African Medical Journal, vol. 72, pp. 355-358, 1995.
[25] J. Vassallo, K. Metze, F. Traina, C. de Souza, and I. Lorand-Metze, "Expression of Epstein-Barr virus in classical Hodgkin-s lymphomas in Brazilian adult patients," Haematologica, vol. 86, pp.1227-1228, 2001.
[26] S. Bossolasco, P. Cinque, M. Ponzoni, M. G. Vigano, A. Lazzarin, A. Linde, and K. I. Falk, "Epstein-Barr virus DNA load in cerebrospinal fluid and plasma of patients with AIDS-related lymphoma," Journal of NeuroVirology, vol. 8, pp. 432- 438, 2002.
[27] C. R. Rao, M. I. Gutierrez, K. Bhatia, F. Fend, J. Franklin, L. Appaji, G. Gallo, G. Oconor, N. Lalitha, and I. Magrath, "Association of Burkitt-s lymphoma with the Epstein-Barr virus in two developing countries," Leukemia and Lymphoma, vol. 39, pp. 329-337, 2002.